

GLP-1s: Weight down, but steps down too? The paradox clinicians face

Written by The Life Science Feed Editorial Team · Published 7 September 2026 · Edited by Mara Voss

GLP-1 receptor agonists have fundamentally reshaped the management of obesity and type 2 diabetes, offering substantial weight reduction and metabolic benefits. But the clinical picture is not without its complexities, particularly regarding patient behaviour beyond the scales.

While these agents effectively reduce body weight, an emerging observation suggests a potential trade-off in physical activity levels, raising questions about the holistic impact on patient health and long-term outcomes.

KEY TAKEAWAYS

- **The Pivot:** GLP-1 receptor agonists reduce body weight, but some patients also decrease their physical activity.
- **The Data:** Patients on GLP-1s often report reduced appetite and increased satiety, which can lead to less spontaneous movement.
- **The Action:** Clinicians should counsel patients on the importance of maintaining physical activity alongside pharmacotherapy for comprehensive health benefits.

GLP-1 receptor agonists, including agents like liraglutide, semaglutide, and tirzepatide, exert their primary effects by mimicking endogenous incretin hormones. This action enhances glucose-dependent insulin secretion, suppresses glucagon release, slows gastric emptying, and promotes satiety through central nervous system pathways. These mechanisms collectively lead to reduced caloric intake and subsequent weight loss, a critical outcome for patients struggling with obesity and its associated comorbidities.

The profound impact on weight has made these drugs a cornerstone in managing metabolic disease. But the physiological changes induced by these agents extend beyond simple caloric restriction. Patients often report a significant decrease in appetite and an earlier onset of satiety, which can alter their relationship with food and, by extension, their energy expenditure. This shift can manifest as less spontaneous physical activity, even as weight declines. For a comprehensive guide to managing these conditions, clinicians may find the Oxford Handbook of Endocrinology and Diabetes a useful reference.

The Energy Balance Equation

Weight loss, regardless of the method, typically involves a reduction in overall energy expenditure. This is a well-established physiological response where the body attempts to conserve energy in the face of reduced caloric intake. With GLP-1 agonists, the primary driver of weight loss is often a substantial reduction in food intake, leading to a negative energy balance. This reduction in intake can be so effective that patients may feel less inclined to engage in physical

activity, perceiving less need to "burn off" calories.

The decrease in physical activity is not necessarily a direct pharmacological effect of the GLP-1 agonist itself. Rather, it appears to be a behavioural adaptation to the altered metabolic state and reduced hunger signals. Patients may simply feel less energetic or motivated to move when their caloric intake is significantly lower, or they may feel satisfied with their weight loss progress and inadvertently deprioritise exercise. This observation aligns with some of our previous coverage on exercise patterns in patients initiating GLP-1s.

Maintaining Muscle Mass and Function

A critical consideration in any weight loss strategy is the preservation of lean muscle mass. While GLP-1 agonists are highly effective at reducing fat mass, some studies indicate that a proportion of the weight lost can be lean body mass. Reduced physical activity exacerbates this issue, as muscle tissue is maintained through regular use. Loss of muscle mass can have significant long-term implications, including reduced metabolic rate, decreased strength, and impaired physical function, particularly in older adults.

Clinicians must therefore counsel patients on the importance of resistance training and regular aerobic exercise to mitigate muscle loss and maintain overall physical fitness. The goal of obesity management extends beyond mere weight reduction; it encompasses improving body composition, functional capacity, and metabolic health. Ignoring the physical activity component risks undermining some of the broader health benefits of weight loss.

Addressing the Behavioural Component

The challenge lies in integrating pharmacotherapy with lifestyle interventions. While GLP-1 agonists provide a powerful tool for appetite control, they do not inherently promote physical activity. This means that behavioural support for exercise remains essential for preserving lean body mass and functional capacity. Patients need clear guidance on how to incorporate regular movement into their routines, even when they feel less driven by hunger or the immediate need to lose more weight.

This requires a proactive approach from healthcare providers, moving beyond simply prescribing the medication. Discussions should include setting realistic activity goals, exploring enjoyable forms of exercise, and addressing potential barriers to physical activity. The long-term success of weight management often depends on sustained lifestyle changes, and physical activity is a non-negotiable component of that equation. Without it, patients risk post-GLP-1 weight regain and a decline in overall physical resilience.

The Unanswered Questions

The precise mechanisms linking GLP-1 agonist use to reduced physical activity require further investigation. Is it purely a behavioural response to reduced hunger, or are there subtle central nervous system effects that influence motivation or energy levels? Understanding these nuances could inform better patient counselling strategies and potentially lead to adjunctive therapies or exercise protocols tailored for patients on these medications.

For now, the message is clear: weight loss with GLP-1s is effective, but it does not absolve patients or clinicians from the responsibility of promoting and maintaining physical activity. The full health benefits of weight reduction are realised when accompanied by improved fitness and preserved muscle mass. The next wave of research should focus on optimising these combined approaches.

CLINICAL IMPLICATIONS

The efficacy of GLP-1 receptor agonists in driving weight loss is undeniable, but clinicians must look beyond the number on the scale. A patient losing weight but becoming sedentary is not achieving optimal health outcomes. We need to integrate robust exercise counselling into every GLP-1 prescription.

The industry, too, has a role. While the focus has been on efficacy and safety for weight reduction, future drug development or adjunctive therapies might consider how to mitigate the observed decline in physical activity. Perhaps combination therapies or specific formulations could address this.

For patients, the message is simple: these medications are powerful tools, but they are not a substitute for movement. Maintaining muscle mass and cardiovascular fitness is vital for long-term health, irrespective of the method of weight loss. GPs should be explicit about this from the outset, setting expectations that weight loss is only one part of the journey.

EDITORIAL & AI STANDARDS

AI tools are used solely to structure and summarise evidence from peer-reviewed primary sources. No AI-generated conclusions appear in The Life Science Feed without editor verification against the primary source.

REFERENCES

1. Veronese N, Ragusa FS, Pegreffi F, et al. Sarcopenic obesity and health outcomes: An umbrella review of systematic reviews with meta-analysis. *J Cachexia Sarcopenia Muscle*. 2024;15(4):1264-1274. doi:10.1002/jcsm.13502
2. Nogueira-de-Almeida CA, Weffort VRS, Ued FDV, et al. What causes obesity in children and adolescents? *J Pediatr (Rio J)*. 2024;100 Suppl 1(Suppl 1):S48-S56. doi:10.1016/j.jped.2023.09.011
3. Hoxha I, Sadiku F, Hoxha L, et al. Breast Cancer and Lifestyle Factors: Umbrella Review. *Hematol Oncol Clin North Am*. 2024;38(1):137-170. doi:10.1016/j.hoc.2023.07.005
4. Chen M, Wu R, Chen R, et al. Acupuncture for Treatment of Obesity: An Umbrella Review. *J Evid Based Med*. 2025;18(4):e70083. doi:10.1111/jebm.70083
5. Bellicha A, van Baak MA, Battista F, et al. Effect of exercise training on weight loss, body composition changes, and weight maintenance in adults with overweight or obesity: An overview of 12 systematic reviews and 149 studies. *Obes Rev*. 2021;22 Suppl 4(Suppl 4):e13256. doi:10.1111/obr.13256
6. Stiglic N, Viner RM. Effects of screentime on the health and well-being of children and adolescents: a systematic review of reviews. *BMJ Open*. 2019;9(1):e023191. doi:10.1136/bmjopen-2018-023191

LICENCE & RIGHTS

© 2026 The Life Science Feed. All rights reserved. This content is produced for medical education purposes. It may not be reproduced, distributed, or transmitted without prior written permission from The Life Science Feed.

MEDICAL DISCLAIMER

This content is intended for healthcare professionals only and does not constitute medical advice. Clinical decisions must be made by qualified practitioners based on individual patient circumstances.

FOLLOW THE LIFE SCIENCE FEED

Instagram @lifesciencefeed **LinkedIn** linkedin.com/company/thelifesciencefeed

thelifesciencefeed.com